Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12937743 | 0.68 | MMP8 (0.38) | MMP8MEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL3937352 | 0.68 | MAPT (0.40) | KMT2AMAPTTLR4 | |
| SCHEMBL16752747 | 0.67 | MEN1 (0.46) | MEN1KMT2AMAPTTSHRHSD17B10 | |
| SCHEMBL10706613 | 0.67 | KMT2A (0.36) | MEN1KMT2AMAPTTLR4BRD4 | |
| SCHEMBL15974383 | 0.65 | HDAC2 (0.37) | MEN1KMT2AMAPTTSHRHSD17B10 | |
| SCHEMBL23466930 | 0.64 | TSHR (0.35) | MEN1KMT2AMAPTCYP2D6TSHR | |
| SCHEMBL271585 | 0.64 | MMP8 (0.59) | MMP8MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL99907 | 0.63 | KMT2A (0.49) | MEN1KMT2AMAPT | |
| SCHEMBL15973797 | 0.63 | KDM4E (0.40) | MEN1KMT2AMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL8689763 | 0.62 | KMT2A (0.41) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145273-A1 | PRECATALYST FOR SHIBASAKI'S RARE EARTH METAL BINOLATE CATALYSTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145273-A1 | PRECATALYST FOR SHIBASAKI'S RARE EARTH METAL BINOLATE CATALYSTS | TBCB, RUVBL2, RHEB | MMP8 4790/4885MEN1 1157/4885KMT2A 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.